1. Home
  2. Medical Research
  3. Seattle, WA
  4. Phenome Health

Phenome Health

Phenome Health has an America's Best Score of 54 out of 100, based on its 2025 Form 990, below the 60-point bar to be ranked.

  • Seattle, WA
  • Tax-exempt since 2022
  • EIN: 87-2732969
phenomehealth.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
54OF 100 Not ranked Below the 60-point bar How this score is calculated

Organization summary

Phenome Health is a 501(c)(3) organization, classified under Medical Research (NTEE H05). Contributions are tax-deductible.

2101 4Th Avenue, Seattle, WA 98121-2352

Among the 17 scored medical research organizations in Seattle, Phenome Health holds 2.4 months of operating reserves (peer median 5.5 months), runs a typical yearly surplus of 14.9% (peers: surplus of 1.3%), and has grown spending 39.9% a year (peers: grown spending 3.8% a year).

In fiscal year 2025 it reported $5,913,544 in revenue and $6,338,192 in expenses, with contributions making up 99.8% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2025 Form 990

Phenome Health's mission is to develop the tools & insights that power data-driven personalized health. We envision a world where everyone is empowered by their own data to improve wellness and prevent disease.

Largest programs · fiscal year 2025

  • Predictive modeling. We continued the past years efforts to build computational models and the required bioinformatic pipelines for the purpose of modeling health trajectories for individuals given personal health data as inputs to models. All data are deidentified with no access to phi or pii by personnel working on the modeling efforts. In 2025, we added access to more public databases to inform… Read more

    Predictive modeling. We continued the past years efforts to build computational models and the required bioinformatic pipelines for the purpose of modeling health trajectories for individuals given personal health data as inputs to models. All data are deidentified with no access to phi or pii by personnel working on the modeling efforts. In 2025, we added access to more public databases to inform our models as deliverables for our current federally funded projects.

    $2,254,436 spent · 47.0% of program spending
  • Type 2 diabetes study. In 2025, we began logistical execution and study set-up of a type II diabetes study that we completed a pilot for in 2024. This study will enroll 1000 patients with diabetes, through clinical partnerships. The first recruited patient will enroll in 2026. The study is intended to dentify subtypes of type II diabetes through profiling blood samples, facilitating to more tailor… Read more

    Type 2 diabetes study. In 2025, we began logistical execution and study set-up of a type II diabetes study that we completed a pilot for in 2024. This study will enroll 1000 patients with diabetes, through clinical partnerships. The first recruited patient will enroll in 2026. The study is intended to dentify subtypes of type II diabetes through profiling blood samples, facilitating to more tailored interventions in a sub-type specific manner.

    $1,247,134 spent · 26.0% of program spending
  • Multiomic data platform build. In 2025 we continued to invest in building a computational environment capable of serving the need to ingest and analyze high dimensional health data. This platform requires continued feature development and maintenance. It is currently serving existing predictive modeling needs and will serve projects we secure funding for in the future. $1,295,101 spent · 27.0% of program spending
  • Pre-diabetes study. In addition to type II diabetes study, in 2025 we began analysis of a set of samples collected by a collaborator over 15 years that represent people-at-risk for diabetes but without a disease diagnosis at the time of enrollment. This study is designed to identify pre-diagnostic, sub-type specific markers in blood that could inform tailored prevention strategies beyond the stand… Read more

    Pre-diabetes study. In addition to type II diabetes study, in 2025 we began analysis of a set of samples collected by a collaborator over 15 years that represent people-at-risk for diabetes but without a disease diagnosis at the time of enrollment. This study is designed to identify pre-diagnostic, sub-type specific markers in blood that could inform tailored prevention strategies beyond the standard current approaches.

Where each dollar went · fiscal year 2025

Of every dollar it spent, 76¢ went to programs, 11¢ to management and 13¢ to fundraising.

  • Programs $4,796,671
  • Management $686,724
  • Fundraising $854,797

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score54 / 100
DesignationNot ranked

Score breakdown

MeasureThis organizationPoints
Operating reserves2.4 mo; 5.5 mo in cash1.7 / 25
Financial balance (median margin)+14.9%16 / 20
Transparency4 full 990s, latest TY202520 / 20
Program growth+39.9% / yr15 / 15
Track record4 years1.6 / 10
Debt load70.3% of assets0 / 10
Total54.3 → 54
Spending on programs
Not scored; America's Best needs 65%+
76%Meets

Compared with Seattle peers

MeasureThis organizationPeer median
Operating reserves2.4 mo5.5 mo
Typical margin+14.9%+1.3%
Spending growth+39.9% / yr+3.8% / yr
Debt load70.3%25.3%

Peers: the 17 Seattle medical research organizations with a score, ranked or below the bar.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$5,913,544Fiscal year 20252022: $3,072,62420222023: $3,720,15520232024: $3,516,87520242025: $5,913,5442025
Expenses$6,338,192Fiscal year 20252022: $2,314,52520222023: $2,974,15920232024: $3,360,60620242025: $6,338,1922025
Total assets$4,325,941Fiscal year 20252022: $942,59620222023: $1,633,56520232024: $2,377,74920242025: $4,325,9412025
Total liabilities$3,040,227Fiscal year 20252022: $184,49720222023: $129,47020232024: $667,38720242025: $3,040,2272025
Fiscal year ending December 2025
Revenue$5,913,544
Expenses$6,338,192
Net income−$424,648
Net assets$1,285,714

Notable sources of revenue

Percent of total revenue
Contributions$5,901,830
Program services$0
Investment income$5,214
Other (net)$6,500

Assets / debt

Total assets$4,325,941
Total liabilities$3,040,227
Net assets$1,285,714

Compensation

Not in our extract for this year.

Fiscal year ending December 2024
Revenue$3,516,875
Expenses$3,360,606
Net income$156,269
Net assets$1,710,362

Notable sources of revenue

Percent of total revenue
Contributions$3,516,837
Program services$0
Investment income$24
Other (net)$14

Assets / debt

Total assets$2,377,749
Total liabilities$667,387
Net assets$1,710,362

Compensation

Not in our extract for this year.

Fiscal year ending December 2023
Revenue$3,720,155
Expenses$2,974,159
Net income$745,996
Net assets$1,504,095

Notable sources of revenue

Percent of total revenue
Contributions$3,719,541
Program services$0
Investment income$12
Other (net)$602

Assets / debt

Total assets$1,633,565
Total liabilities$129,470
Net assets$1,504,095

Compensation

Officers and key employees$720,624
Share of expenses24.2%
Fiscal year ending December 2022
Revenue$3,072,624
Expenses$2,314,525
Net income$758,099
Net assets$758,099

Notable sources of revenue

Percent of total revenue
Contributions$3,072,624
Program services$0
Investment income$0
Other (net)$0

Assets / debt

Total assets$942,596
Total liabilities$184,497
Net assets$758,099

Compensation

Officers and key employees$890,749
Share of expenses38.5%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?